1. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. (20th October 2022) Authors: Oaknin, Ana; Lorusso, Domenica; Oza, Amit; Colombo, Nicoletta; van Gorp, Toon; O'Malley, David; Banerjee, Susana; Murphy, Conleth; Harter, Philipp; Konecny, Gottfried; Kaminsky, Marie-Christine; Method, Michael; Wang, Jiuzhou; Coleman, Robert L; Birrer, Michael; Matulonis, Ursula; Moore, Kathleen Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers. (4th December 2020) Authors: Banerjee, Susana; Oaknin, Ana; Sanchez-Simon, Inmaculada; Salgado, Alfonso Cortes; Patel, Sandip Pravin; Oza, Amit; Das, Mayukh; Kourtesis, Panagiotis; Ascierto, Maria Libera; Diamond, Jennifer R Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 4 Page Start: A86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. Issue 1 (December 2016) Authors: Goss, Glenwood; Jonker, Derek; Laurie, Scott; Weberpals, Johanne; Oza, Amit; Spaans, Johanna; Porte, Charles; Dimitroulakos, Jim Journal: Journal of translational medicine Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. (November 2020) Authors: Tjokrowidjaja, Angelina; Lee, Chee K.; Friedlander, Michael; Gebski, Val; Gladieff, Laurence; Ledermann, Jonathan; Penson, Richard; Oza, Amit; Korach, Jacob; Huzarski, Tomasz; Manso, Luis; Pisano, Carmela; Asher, Rebecca; Lord, Sarah J.; Kim, Se Ik; Lee, Jung-Yun; Colombo, Nicoletta; Park-Simon, ... Journal: European journal of cancer Issue: Volume 139(2020) Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Conservative management of adnexal masses. Issue 3 (March 2019) Authors: May, Taymaa; Oza, Amit Journal: Lancet oncology Issue: Volume 20:Issue 3(2019) Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Emerging growth factor receptor antagonists for ovarian cancer treatment. (2nd January 2018) Authors: Bonilla, Luisa; Oza, Amit; Lheureux, Stephanie Journal: Expert opinion on emerging drugs Issue: Volume 23:Number 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (January 2017) Authors: Marth, Christian; Vergote, Ignace; Scambia, Giovanni; Oberaigner, Willi; Clamp, Andrew; Berger, Regina; Kurzeder, Christian; Colombo, Nicoletta; Vuylsteke, Peter; Lorusso, Domenica; Hall, Marcia; Renard, Vincent; Pignata, Sandro; Kristeleit, Rebecca; Altintas, Sevilay; Rustin, Gordon; Wenham, Rob... Journal: European journal of cancer Issue: Volume 70(2017) Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. (9th February 2018) Authors: Moore, Kathleen N; Vergote, Ignace; Oaknin, Ana; Colombo, Nicoletta; Banerjee, Susana; Oza, Amit; Pautier, Patricia; Malek, Karim; Birrer, Michael J Journal: Future oncology Issue: Volume 14:Number 17(2018) Page Start: 1669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Global health and equity in access to genomics and clinical trials with novel therapies. (March 2018) Authors: Oza, Amit Journal: Lancet Issue: Volume 6(2018)Supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. (1st November 2014) Authors: Okamoto, Aikou; Glasspool, Rosalind M.; Mabuchi, Seiji; Matsumura, Noriomi; Nomura, Hiroyuki; Itamochi, Hiroaki; Takano, Masashi; Takano, Tadao; Susumu, Nobuyuki; Aoki, Daisuke; Konishi, Ikuo; Covens, Alan; Ledermann, Jonathan; Mezzazanica, Delia; Steer, Christopher; Millan, David; McNeish, Iain ... Journal: International journal of gynecological cancer Issue: Volume 24(2014)Supplement 3 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗